KAIST Holotomography: Can Non-Invasive 3D Imaging Improve Embryo Selection for IVF?

In IVF, selecting the right embryo for transfer heavily impacts your chances of success. Honoured at the 2026 ESHRE annual meeting, KAIST’s holotomography offers quantitative three-dimensional views of live embryos without dyes or damage.

This promising technology solves a long-standing IVF-lab challenge: assessing an embryo’s developmental potential more accurately without harming it.

While early mouse-study results are encouraging, the technique is not yet available for patients. This article covers how it works, key research findings, and important real-world limitations.

Why New Assessment Methods Are Needed?

Selecting the embryo with the highest developmental potential for transfer is one of the most critical steps within IVF treatment. However, today’s standard clinical embryo-assessment methods carry clear limitations.

Staining or special fluorescent dyes can show fine cell details, but these treatments may hurt embryos, so they are not used for real IVF cycles.

Meanwhile, embryo assessment in IVF has long been limited by 2-dimensional, experience-driven observation. Right now, clinics mostly look at flat 2-D microscope images to grade embryos. This method depends heavily on an embryologist’s eyes and experience, and important details hidden inside the embryo cannot be seen.

The IVF field has been looking for simpler, more objective ways to judge embryo potential.

How Holotomography Works?

The KAIST research group deployed a technology known as holotomography. Its underlying principle is intuitive. It measures light refraction as light travels through cells, reconstructing the internal 3-D architecture of living embryos.

Refractive index is a quantifiable value that shifts according to intracellular material density and composition. By measuring refractive index, researchers can detect subtle cellular-structure changes without applying dyes or labelling agents of any kind.

Where conventional microscopes only show an embryo’s outer shape and surface features, holotomography visualises the three-dimensional distribution and organisation of materials inside the embryo.

What the Study Found?

KAIST validated this imaging approach using mouse embryos. Findings have been published in Communications Biology.

1. Healthy and slow-growing embryos look different in 3-D

The team performed sequential 3-D imaging of mouse embryos from the 2-cell stage through blastocyst formation. Key observations:

Normally developing embryos: higher blastomere count (cleavage-derived embryonic cells), with tightly packed nuclei.

Arrested embryos: enlarged blastomeres, increased heterogeneity in cytoplasmic refractive index, and fewer, larger nuclei.

These structural distinctions are difficult to spot by visual inspection of standard two-dimensional images.

2. Machine-learning models can forecast blastocyst development

When feeding these 3-D imaging features into machine-learning models, predictive performance for blastocyst formation reached an AUC of 0.958-0.963 (An AUC value closer to 1.0 indicates higher predictive accuracy).

For context, the preprint cites an approximate 30% live-birth rate per IVF cycle; the quality of embryo assessment directly impacts this clinical outcome.

Note: The 30% live-birth rate reference originates from the study’s bioRxiv preprint context. Real-world IVF live-birth rates vary significantly with patient age and clinical circumstances.

3. Imaging does not hinder embryonic development

Investigators compared embryos imaged via holotomography against conventionally cultured controls. Blastocyst formation rates stood at 89.3% and 85.15%, respectively, with no statistically meaningful difference.

This demonstrates the imaging workflow is safe and does not compromise an embryo’s developmental capacity.

Positioning and limitations of the technology

Key benefit: It gathers measurable, 3-D information from inside the embryo, without physical contact or chemical labelling.

Regular embryo grading is subjective: a specialist looks at a photo and gives an opinion. Holotomography produces hard numbers, such as light-bending measurements and how tightly cell nuclei sit. Those numbers can feed computer tools to support decision-making.

Important real-world limits: All existing data comes from mouse-embryo experiments. No large-scale human clinical trials yet.

We still lack proof that embryos picked using this tool will actually raise live-birth rates for patients. It cannot be used in routine IVF labs today. More human research must be finished first.

How It Compares with Other Embryo Assessment Technologies

Holotomography fills a unique niche: it delivers both three-dimensional quantification and complete non-invasiveness.

Time-lapse imaging is also non-invasive yet remains two-dimensional. PGT-A provides chromosomal readouts but demands embryo cell biopsy.

Holotomography unlocks the previously hard-to-access dimension of internal 3-D embryo structure, all without touching the embryo.

What This Could Mean for the Future of IVF

The ESHRE Basic Science Award recognises that this new technical approach works in early-stage research. It shows promise as a possible add-on tool to complement our usual 2-D embryo checks, without harming embryos.

If human-embryo testing goes well, holotomography might one day become an extra assessment tool inside IVF labs. Right now, however, it remains in research labs, patients cannot book or receive this test as clinical care.

For families preparing for IVF, this innovation signals a broader industry shift: embryo evaluation is gradually moving away from “subjective visual judgement” toward “data-driven decision-making.”

Curious about evolving embryo-assessment options for IVF? Connect with the CEF fertility team. Email info@cefivf.com or visit our Contact page.

Disclaimer: This educational article draws on KAIST’s July 2026 news release and peer-reviewed research published in Communications Biology. This content is purely informational and does not constitute personalised medical advice. Always consult a licensed reproductive-endocrinology specialist for your IVF care decisions.